儿科慢性肾病治疗创新路线图
A roadmap for therapeutic innovation in paediatric chronic kidney disease
文章总结了儿科慢性肾病的治疗创新路线图,涵盖了流行病学、临床试验、药物研发等多个方面,为未来研究提供了方向。
Boenink, R. et al. The ERA registry annual report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons. Clin. Kidney J. 18, sfae405 (2025).
ESCAPE Trial Group Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639–1650 (2009).
Gross, O., Haffner, D., Schaefer, F. & Weber, L. T. SGLT2 inhibitors: approved for adults and cats but not for children with CKD. Nephrol. Dial. Transpl. 39, 907–909 (2024).
Harambat, J. & Madden, I. What is the true burden of chronic kidney disease in children worldwide? Pediatr. Nephrol. 38, 1389–1393 (2023).
United States Renal Data System. 2025 USRDS Annual Data Report: epidemiology of kidney disease in the United States. https://usrds-adr.niddk.nih.gov/2025/ (2025).
Furth, S. L. et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2132–2140 (2011).
Schaefer, F. et al. Cardiovascular phenotypes in children with CKD: the 4C study. Clin. J. Am. Soc. Nephrol. 12, 19–28 (2017).
Furth, S. L. et al. Estimating time to ESRD in children with CKD. Am. J. Kidney Dis. 71, 783–792 (2018).
Shayman, J. A. Moving the needle: accelerating drug discovery in nephrology. J. Am. Soc. Nephrol. 34, 363–365 (2023).
Mullard, A. 2021 FDA approvals. Nat. Rev. Drug. Discov. 21, 83–88 (2022).
Levin, A. et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 105, 684–701 (2024).
Chesnaye, N. C. et al. Mortality risk in European children with end-stage renal disease on dialysis. Kidney Int. 89, 1355–1362 (2016).
United States Renal Data System. 2026 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. https://usrds-adr.niddk.nih.gov/2026 (2026).
Weaver, D. J., Somers, M. J. G., Martz, K. & Mitsnefes, M. M. Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry. Pediatr. Nephrol. 32, 2319–2330 (2017).
Abd ElHafeez, S. et al. Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. Nephrol. Dial. Transpl. 39, 1449–1460 (2024).
Mencarelli, F. et al. Dyslipidemia in children with chronic kidney disease-findings from the cardiovascular comorbidity in children with chronic kidney disease (4C) study. Pediatr. Nephrol. 39, 2759–2772 (2024).
Mitsnefes, M. M. Cardiovascular disease risk factors in chronic kidney disease in children. Semin. Nephrol. 41, 434–438 (2021).
Logeman, C. et al. Developing consensus-based outcome domains for trials in children and adolescents with CKD: an international Delphi survey. Am. J. Kidney Dis. 76, 533–545 (2020).
Hanson, C. S. et al. Establishing core outcome domains in pediatric kidney disease: report of the standardized outcomes in nephrology-children and adolescents (SONG-KIDS) consensus workshops. Kidney Int. 98, 553–565 (2020).
Hughes, A. et al. Establishing a core outcome measure for life participation in children with chronic kidney disease: a standardized outcomes in nephrology-children and adolescents with chronic kidney disease (SONG-Kids) consensus workshop report. Kidney Int. 109, 273–282 (2026).
Tong, A. et al. Standardised outcomes in nephrology-children and adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials 17, 401 (2016).
Gross, O. et al. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol. Dial. Transpl. 40, 679–687 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07107945 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05196035 (2026).
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05457283 (2026).
Smoyer, W. E. et al. Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023. Kidney Int. 109, 57–63 (2026).
Levey, A. S. et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84–104 (2020).
European Medicines Agency. Qualification opinion for GFR slope as a validated surrogate endpoint for RCT in CKD (EMA/SA/00000104642). https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf (2023).
McArdle, Z., Schreuder, M. F., Moritz, K. M., Denton, K. M. & Singh, R. R. Physiology and pathophysiology of compensatory adaptations of a solitary functioning kidney. Front. Physiol. 11, 725 (2020).
International Society of Glomerular Disease. PARASOL-FSGS: Proteinuria and Other Biomarkers as Endpoints for Clinical Trials in Kidney Disease. https://www.is-gd.org/parasol-fsgs (2026).
Smith, A. et al. #1721 Proteinuria as a clinical trial endpoint in focal segmental glomerulosclerosis: validation of PARASOL findings in RaDaR. Nephrol. Dial. Transpl. 40, gfaf116.032 (2025).
Fuhrman, D. Y. et al. Preoperative renal functional reserve as a predictor of acute kidney injury in young adults with congenital heart disease. Sci. Rep. 15, 23690 (2025).
Tufro, A., Arrizurieta, E. E. & Repetto, H. Renal functional reserve in children with a previous episode of haemolytic-uraemic syndrome. Pediatr. Nephrol. 5, 184–188 (1991).
Figurek, A., Luyckx, V. A. & Mueller, T. F. A systematic review of renal functional reserve in adult living kidney donors. Kidney Int. Rep. 5, 448–458 (2020).
De Moor, B., Vanwalleghem, J. F., Swennen, Q., Stas, K. J. & Meijers, B. K. I. Haemodynamic or metabolic stimulation tests to reveal the renal functional response: requiem or revival? Clin. Kidney J. 11, 623–654 (2018).
Mueller, T. F. & Luyckx, V. A. Potential utility of renal functional reserve testing in clinical nephrology. Curr. Opin. Nephrol. Hypertens. 33, 130–135 (2024).
Luyckx, V. A. et al. Nephron overload as a therapeutic target to maximize kidney lifespan. Nat. Rev. Nephrol. 18, 171–183 (2022).
Sheila, M. et al. Association of UACR and UPCR with kidney failure: analysis of observational data in children with chronic kidney disease. Nephrol. Dial. Transpl. 41, ii41–ii49 (2026).
Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077–2090 (2023).
Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. 392, 531–543 (2025).
Heerspink, H. J. L. et al. Atrasentan in patients with IgA nephropathy. N. Engl. J. Med. 392, 544–554 (2025).
Kavanagh, D. et al. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. Lancet 406, 1587–1598 (2025).
Ardissino, G. et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. Pediatr. Nephrol. 19, 172–177 (2004).
Wong, C. S. et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin. J. Am. Soc. Nephrol. 4, 812–819 (2009).
Fathallah-Shaykh, S. A. et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin. J. Am. Soc. Nephrol. 10, 571–577 (2015).
Warady, B. A. et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am. J. Kidney Dis. 65, 878–888 (2015).
Wingen, A. M., Fabian-Bach, C., Schaefer, F. & Mehls, O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European study group of nutritional treatment of chronic renal failure in childhood. Lancet 349, 1117–1123 (1997).
van den Belt, S. M. et al. Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J. Am. Soc. Nephrol. 29, 2225–2233 (2018).
Gross, O. et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int. 97, 1275–1286 (2020).
Gross, O. et al. Prospective cohort study in Alport syndrome patients under standard therapy. Kidney Int. Rep. 10, 1360–1371 (2025).
Degraeuwe, E. et al. Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study. Pediatr. Nephrol. 40, 797–809 (2025).
Caring for Australians with Renal Impairment (CARI) The CARI guidelines. Urine protein as diagnostic test: testing for proteinuria. Nephrology 9, S3–S7 (2004).
Mori, Y. et al. Urinary creatinine excretion and protein/creatinine ratios vary by body size and gender in children. Pediatr. Nephrol. 21, 683–687 (2006).
McDonnell, T. The impact of primary renal diagnosis on prognosis and the varying predictive power of albuminuria in the NURTuRE-CKD study. Am. J. Nephrol. 56, 1–12 (2024).
Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137 (2011).
Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).
Gribouval, O. et al. APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrol. Dial. Transpl. 34, 1885–1893 (2019).
Nadkarni, G. N. et al. Worldwide frequencies of APOL1 renal risk variants. N. Engl. J. Med. 379, 2571–2572 (2018).
Trautmann, A. et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J. Am. Soc. Nephrol. 28, 3055–3065 (2017).
De Mutiis, C. et al. Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology 61, 2563–2571 (2022).
Hari, P. et al. IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 40, 865–872 (2025).
Garrity, K. et al. Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database. Pediatr. Nephrol. 40, 1949–1958 (2025).
Chen, D. P. et al. Age of onset and disease course in biopsy-proven minimal change disease: an analysis from the cure glomerulonephropathy network. Am. J. Kidney Dis. 81, 695–706.e1 (2023).
Bartels, J. et al. GDF-15 and uEGF independently associate with CKD progression in children. Kidney Int. Rep. 10, 3369–3378 (2025).
Speer, T. et al. Urinary DKK3 as a biomarker for short-term kidney function decline in children with chronic kidney disease: an observational cohort study. Lancet Child. Adolesc. Health 7, 405–414 (2023).
Schaefer, F. SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities. Kidney Int. 109, 2–5 (2026).
European Medicines Agency. Engagement framework: European Medicines Agency and patients, consumers and their organisations (EMA/649909/2021). https://www.ema.europa.eu/en/documents/other/engagement-framework-european-medicines-agency-and-patients-consumers-and-their-organisations_en.pdf (2022).
US Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome (2026).
US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. https://www.fda.gov/media/77832/download (2009).
Soyfer, B. et al. Qualitative analysis and comparison of externally led patient-focused drug development concepts for autosomal recessive polycystic kidney disease against SONG initiatives. Kidney Med. 7, 101110 (2025).
Hudson, A. C. et al. School attendance and sport participation amongst children with chronic kidney disease: a cross-sectional analysis from the Kids with CKD (KCAD) study. Pediatr. Nephrol. 39, 1229–1237 (2024).
European Medicines Agency. ICH E11A guideline on pediatric extrapolation (EMA/CHMP/ICH/205218/2022). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e11a-pediatric-extrapolation-step-5_en.pdf (2024).
EMPA-KIDNEY Collaborative Group Long-term effects of empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 392, 777–787 (2025).
Zhang, B. & Deng, L. Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety. Front. Med. 12, 1574693 (2025).
Simões e Silva, A. C., Valério, F. C., Vasconcelos, M. A., Miranda, D. M. & Oliveira, E. A. Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease. Clin. Dev. Immunol. 2013, 597920 (2013).
Fakhouri, F. et al. Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. N. Engl. J. Med. 393, 2210–2220 (2025).
Schijvens, A. M., de Wildt, S. N. & Schreuder, M. F. Pharmacokinetics in children with chronic kidney disease. Pediatr. Nephrol. 35, 1153–1172 (2020).
Jacobs, T. G. et al. Lamivudine and emtricitabine dosing proposal for children with HIV and chronic kidney disease, supported by physiologically based pharmacokinetic modelling. Pharmaceutics 15, 1424 (2023).
Tuchman, S. et al. The advancing the development of pediatric therapeutics 8 (ADEPT 8) workshop on drug dosing in pediatric patients with renal impairment. J. Pediatr. 283, 114624 (2025).
European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes (EMA/99865/2025). https://www.ema.europa.eu/en/documents/other/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes_en.pdf (2025).
Querfeld, U. et al. The cardiovascular comorbidity in children with chronic kidney disease (4C) study: objectives, design, and methodology. Clin. J. Am. Soc. Nephrol. 5, 1642–1648 (2010).
Atkinson, M. A., Ng, D. K., Warady, B. A., Furth, S. L. & Flynn, J. T. The CKiD study: overview and summary of findings related to kidney disease progression. Pediatr. Nephrol. 36, 527–538 (2021).
Kang, H. G. et al. KNOW-Ped CKD (KoreaN cohort study for outcomes in patients with pediatric CKD): design and methods. BMC Nephrol. 17, 35 (2016).
Smith, J. M., Stablein, D. M., Munoz, R., Hebert, D. & McDonald, R. A. Contributions of the transplant registry: the 2006 annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr. Transpl. 11, 366–373 (2007).
Ardissino, G. et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111, e382–e387 (2003).
Trautmann, A. et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin. J. Am. Soc. Nephrol. 10, 592–600 (2015).
Gadegbeku, C. A. et al. Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach. Kidney Int. 83, 749–756 (2013).
Mariani, L. H. et al. CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease. Am. J. Kidney Dis. 73, 218–229 (2019).
Bassanese, G. et al. The European rare kidney disease registry (ERKReg): objectives, design and initial results. Orphanet J. Rare Dis. 16, 251 (2021).
Wong, K. et al. Description and cross-sectional analyses of 25,880 adults and children in the UK national registry of rare kidney diseases cohort. Kidney Int. Rep. 9, 2067–2083 (2024).
Ebner, K. et al. Recent progress of the ARegPKD registry study on autosomal recessive polycystic kidney disease. Front. Pediatr. 5, 18 (2017).
De Rechter, S. et al. ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int. Rep. 4, 1271–1284 (2019).
Gross, O. et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 81, 494–501 (2012).
Okuda, Y. et al. Investigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS). Clin. Exp. Nephrol. 30, 87–95 (2026).
European Medicines Agency. Concept paper on the development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making (EMA/125200/2026). https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf (2026).
US Food and Drug Administration. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug (2023).
European Medicines Agency. Guideline on registry-based studies (EMA/426390/2021). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en.pdf (2021).
European Medicines Agency. Journey towards a roadmap for regulatory guidance on real-world evidence (EMA/100019/2025). https://www.ema.europa.eu/en/documents/other/journey-towards-roadmap-regulatory-guidance-real-world-evidence_en.pdf (2025).
European Medicines Agency. Data Quality Framework for EU medicines regulation: application to real-world data (EMA/503781/2024). https://www.ema.europa.eu/en/documents/other/data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf (2026).
European Rare Kidney Disease Reference Network. esCapeKD: a prospective cohort study of children with chronic kidney disease. https://www.erknet.org/subregistries/escapkd (2026).
US Food and Drug Administration. Interacting with the FDA on complex innovative trial designs for drugs and biological products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products (2020).
European Medicines Agency. Complex clinical trials — questions and answers (EMA/298712/2022). https://health.ec.europa.eu/system/files/2022-06/medicinal_qa_complex_clinical-trials_en.pdf (2022).
European Medicines Agency. ICH E20 guideline on adaptive designs for clinical trials — Step 2b (EMA/CHMP/ICH/206586/2025). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e20-guideline-adaptive-designs-clinical-trials-step-2b_en.pdf (2025).
Röver, C. & Friede, T. Dynamically borrowing strength from another study through shrinkage estimation. Stat. Methods Med. Res. 29, 293–308 (2020).
Pencina, M. J. & Thompson, B. T. Clinical trials in the 21st century — promising avenues for better studies. NEJM Evid. 1, EVIDctw2200060 (2022).
Lin, J. & Radhakrishnan, J. What are baskets, umbrellas, and platforms doing in nephrology clinical trials? J. Am. Soc. Nephrol. 36, 1652–1654 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04573920 (2026).
Friede, T. et al. Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet J. Rare Dis. 13, 186 (2018).
INVENTS Consortium. Innovative designs, extrapolation, simulation methods and evidence-tools for rare diseases addressing regulatory needs (INVENTS). https://invents-he.eu/ (2026).
RealiseD Consortium. RealiseD: transforming clinical trials for ultra-rare diseases. https://realised-ihi.eu/ (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06058585 (2026).
Curovic, V. R. et al. Optimization of albuminuria-lowering treatment in diabetes by crossover rotation to four different drug classes: a randomized crossover trial. Diabetes Care 46, 593–601 (2023).
Robinson, C. H. et al. Using Bayesian pre-trial simulations to optimize the design of adaptive clinical trials in childhood nephrotic syndrome. Contemp. Clin. Trials 153, 107918 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06635720 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07355296 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05312879 (2026).
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 99, S1–S87 (2021).
Torra, R. et al. Diagnosis, management and treatment of the Alport syndrome — 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol. Dial. Transpl. 40, 1091–1106 (2025).
Ding, W. Y. et al. Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Sci. Transl. Med. 15, eabc8226 (2023).
Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).
Ranchin, B. et al. Devices for long-term hemodialysis in small children—a plea for action. Kidney Int. 103, 1038–1040 (2023).
Shroff, R., Walle, J. V., Ranchin, B. & Schmitt, C. P. Addressing the crisis in paediatric dialysis: a call for urgent action. Lancet Child. Adolesc. Health 9, 822–824 (2025).
European Commission. Reform of the EU pharmaceutical legislation. https://health.ec.europa.eu/medicinal-products/legal-framework-governing-medicinal-products-human-use-eu/reform-eu-pharmaceutical-legislation_en (2026).
Attar, S. et al. Developing and streamlining clinical trial services to support pediatric drug development across 21 countries in Europe: insights from the conect4children (c4c) network. Front. Med. 12, 1531276 (2025).
Paumard, L. et al. The route to financial sustainability of a large Public Private Partnership — the example of the clinical trial network conect4children (c4c). Front. Med. 12, 1599997 (2025).
Turner, M. A. et al. European research networks to facilitate drug research in children. Br. J. Clin. Pharmacol. 88, 4258–4266 (2022).
Ceci, A. et al. The task-force in Europe for drug development for the young (TEDDY) network of excellence. Paediatr. Drugs 11, 18–21 (2009).
European Medicines Agency. Medicines. https://www.ema.europa.eu/en/medicines (2026).
US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (2026).
European Medicines Agency. EMEA-001213-PIP03-23 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001213-pip03-23 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05766839 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03813407 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04523727 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04580420 (2025)
European Medicines Agency. EMEA-000370-PIP02-18-M01 - paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000370-pip02-18-m01 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06465472 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04782258 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04817618 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05809531 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05183646 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05003986 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06983028 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07498335 (2026).
European Medicines Agency. EMEA-002500-PIP01-18 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002500-pip01-18 (2020).
European Medicines Agency. EMEA-003396-PIP01-23 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003396-pip01-23 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06994845 (2026).
European Medicines Agency. EMEA-003502-PIP02-24 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003502-pip02-24 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07024563 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07770815 (2026).
European Medicines Agency. EMEA-003300-PIP01-22 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003300-pip01-22 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04958265 (2026).
European Medicines Agency. EMEA-001207-PIP03-20 — paediatric investigation plan. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001207-pip03-20 (2020).
Kotwal, S. S. et al. The global kidney patient trials network and the CAPTIVATE platform clinical trial design: a trial protocol. JAMA Netw. Open. 7, e2449998 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04195906 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06500702 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT01858532 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04591171 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05018221 (2025).
Denburg, M. R. et al. Comparative effectiveness of antihypertensive medications in children with chronic kidney disease. JAMA Pediatr. 180, 546–555 (2026).
来源:Nature 健康护理主题 · nature.com